Analysis of 12-month, Phase 3 study shows 2-fold increase in time between VALTOCO treated seizure clusters, or SEIzure interVAL (SEIVAL) SAN DIEGO, Oct. 12, 2022 /PRNewswire/ -- Neurelis, Inc., a ...
SAN DIEGO, May 5, 2022 /PRNewswire/ -- Neurelis, Inc., today announced findings from a novel, exploratory analysis of VALTOCO® (diazepam nasal spray). The data indicates that patients using the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results